Total Payments
$473,811
2024 Payments
$29,909
Companies
25
Transactions
990
Medicare Patients
1,773
Medicare Billing
$241,819
Payment Breakdown by Category
Other$361,307 (76.3%)
Travel$56,467 (11.9%)
Consulting$36,012 (7.6%)
Food & Beverage$16,363 (3.5%)
Research$2,870 (0.6%)
Education$791.77 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $358,969 | 164 | 75.8% |
| Travel and Lodging | $56,467 | 219 | 11.9% |
| Consulting Fee | $36,012 | 14 | 7.6% |
| Food and Beverage | $16,363 | 562 | 3.5% |
| Unspecified | $2,870 | 15 | 0.6% |
| Honoraria | $2,338 | 2 | 0.5% |
| Education | $791.77 | 14 | 0.2% |
Payments by Type
General
$470,940
975 transactions
Research
$2,870
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $179,116 | 281 | $0 (2024) |
| Janssen Products, LP | $146,233 | 142 | $0 (2023) |
| ViiV Healthcare Company | $77,381 | 124 | $0 (2024) |
| Allergan, Inc. | $28,704 | 111 | $0 (2020) |
| Insmed, Inc. | $19,529 | 53 | $0 (2021) |
| Shionogi Inc | $5,160 | 12 | $0 (2024) |
| Theravance Biopharma Inc. | $4,523 | 6 | $0 (2017) |
| Astellas Pharma US Inc | $4,468 | 13 | $0 (2019) |
| The Medicines Company | $2,659 | 13 | $0 (2017) |
| Melinta Therapeutics, LLC | $2,069 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,909 | 32 | Gilead Sciences, Inc. ($24,900) |
| 2023 | $40,083 | 71 | Gilead Sciences, Inc. ($22,235) |
| 2022 | $60,478 | 65 | Janssen Products, LP ($25,204) |
| 2021 | $50,525 | 70 | ViiV Healthcare Company ($31,504) |
| 2020 | $40,270 | 119 | Gilead Sciences, Inc. ($28,035) |
| 2019 | $115,354 | 253 | Gilead Sciences, Inc. ($52,740) |
| 2018 | $58,340 | 186 | Janssen Products, LP ($24,784) |
| 2017 | $78,852 | 194 | Janssen Products, LP ($55,231) |
All Payment Transactions
990 individual payment records from CMS Open Payments — Page 1 of 40
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: HIV | ||||||
| 11/21/2024 | Gilead Sciences, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,980.00 | General |
| 11/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $112.00 | General |
| 11/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.84 | General |
| 11/11/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,570.00 | General |
| Category: HIV | ||||||
| 10/15/2024 | Shionogi Inc | — | Consulting Fee | Cash or cash equivalent | $4,725.00 | General |
| 10/03/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: ANTIFUNGALS | ||||||
| 09/06/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: HIV | ||||||
| 09/05/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $23.88 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 08/15/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $24.22 | General |
| Category: HIV | ||||||
| 07/16/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $53.04 | General |
| Category: Infections and Infectious Diseases | ||||||
| 07/15/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 07/10/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Travel and Lodging | In-kind items and services | $202.34 | General |
| Category: HIV | ||||||
| 06/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.94 | General |
| 06/05/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,570.00 | General |
| Category: HIV | ||||||
| 06/05/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,570.00 | General |
| Category: HIV | ||||||
| 06/03/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: HIV | ||||||
| 06/03/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: HIV | ||||||
| 05/24/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $24.86 | General |
| Category: Infections and Infectious Diseases | ||||||
| 05/01/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.91 | General |
| 04/17/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,570.00 | General |
| Category: HIV | ||||||
| 04/15/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $78.09 | General |
| Category: HIV | ||||||
| 04/08/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Consulting Fee | Cash or cash equivalent | $1,140.00 | General |
| Category: HIV | ||||||
| 04/02/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,210.00 | General |
| Category: HIV | ||||||
| 03/22/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Travel and Lodging | In-kind items and services | $307.77 | General |
| Category: HIV | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL | GlaxoSmithKline, LLC. | $1,480 | 5 |
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $1,391 | 10 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 510 | 1,009 | $170,646 | $67,469 |
| 2022 | 8 | 449 | 946 | $155,039 | $59,729 |
| 2021 | 6 | 418 | 961 | $154,859 | $61,889 |
| 2020 | 6 | 396 | 828 | $137,651 | $52,733 |
Total Patients
1,773
Total Services
3,744
Medicare Billing
$241,819
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 171 | 576 | $81,792 | $34,467 | 42.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 107 | 108 | $29,052 | $10,656 | 36.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 78 | 164 | $22,869 | $9,709 | 42.5% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 80 | 83 | $16,517 | $5,260 | 31.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 25 | 27 | $10,746 | $3,491 | 32.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 21 | $4,305 | $1,903 | 44.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 16 | 17 | $3,519 | $1,341 | 38.1% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 13 | 13 | $1,846 | $642.60 | 34.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 138 | 527 | $74,834 | $28,300 | 37.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 89 | 176 | $24,683 | $10,416 | 42.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 78 | 83 | $22,327 | $8,117 | 36.4% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 53 | 62 | $12,338 | $4,514 | 36.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 23 | $9,154 | $3,476 | 38.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 33 | 39 | $8,073 | $3,325 | 41.2% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 23 | 23 | $3,266 | $1,227 | 37.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 12 | 13 | $364.00 | $354.31 | 97.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 146 | 572 | $81,224 | $32,013 | 39.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 95 | 200 | $27,946 | $12,028 | 43.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 80 | 87 | $23,403 | $9,111 | 38.9% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 69 | 74 | $14,726 | $5,827 | 39.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 14 | 14 | $5,572 | $2,184 | 39.2% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 14 | 14 | $1,988 | $726.57 | 36.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 138 | 442 | $62,764 | $25,010 | 39.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 102 | 216 | $30,112 | $10,278 | 34.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 81 | 91 | $24,479 | $9,558 | 39.0% |
About Dr. Jeffrey Stephens, MD
Dr. Jeffrey Stephens, MD is a Infectious Disease healthcare provider based in Macon, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538239389.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Stephens, MD has received a total of $473,811 in payments from pharmaceutical and medical device companies, with $29,909 received in 2024. These payments were reported across 990 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($358,969).
As a Medicare-enrolled provider, Stephens has provided services to 1,773 Medicare beneficiaries, totaling 3,744 services with total Medicare billing of $241,819. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Macon, GA
- Active Since 11/09/2006
- Last Updated 07/18/2014
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1538239389
Products in Payments
- Biktarvy (Drug) $112,615
- CABENUVA (Biological) $52,789
- SYMTUZA (Drug) $38,112
- PREZCOBIX (Drug) $29,304
- Symtuza (Drug) $28,668
- AVYCAZ (Drug) $28,568
- Arikayce (Drug) $17,385
- DOVATO (Drug) $15,069
- CABENUVA (Drug) $4,795
- VIBATIV (Drug) $4,541
- Veklury (Drug) $2,700
- VABOMERE (Drug) $2,601
- Sunlenca (Drug) $2,375
- Vabomere (Drug) $1,900
- APRETUDE (Biological) $689.71
- Fetroja (Drug) $434.70
- ZERBAXA (Drug) $274.79
- ISENTRESS (Drug) $254.93
- JULUCA (Drug) $212.16
- TRIUMEQ (Drug) $211.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Macon
Harold Katner, Md, MD
Infectious Disease — Payments: $38,083
Infectious Disease $38,083
Ritu Kumar, Md, MD
Infectious Disease — Payments: $2,199
Infectious Disease $2,199
Michael Stevens, Md, MD
Infectious Disease — Payments: $886.21
Infectious Disease $886.21
Farhan Siddiqui, Md, MD
Infectious Disease — Payments: $689.80
Infectious Disease $689.80
Craig Smith, Md, MD
Infectious Disease — Payments: $59.42
Infectious Disease $59.42